利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

49 条记录 (耗时 0.045 秒)

    Thiazole compounds and methods of use
    3.
    发明授权
    Thiazole compounds and methods of use 失效
    噻唑化合物和使用方法

    公开(公告)号：US08088806B2

    公开(公告)日：2012-01-03

    申请号：US11431155

    申请日：2006-05-09

    申请人： Suoming Zhang ,  Avinash Phadke ,  Cuixian Liu ,  Xiangzhu Wang ,  Jesse Quinn ,  Dawei Chen ,  Venkat Gadhachanda ,  Shouming Li ,  Milind Deshpande

    发明人： Suoming Zhang ,  Avinash Phadke ,  Cuixian Liu ,  Xiangzhu Wang ,  Jesse Quinn ,  Dawei Chen ,  Venkat Gadhachanda ,  Shouming Li ,  Milind Deshpande

    IPC分类号： A61K31/426 ,  A61K31/44

    CPC分类号： C07D487/04 ,  C07D277/38 ,  C07D277/42 ,  C07D417/04 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D513/04

    摘要： The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar1, R2, R3, R4, r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.

    摘要翻译： 本发明提供式I的化合物，盐和水合物，其中变量Ar1，R2，R3，R4，r，q和t在本文中定义。 某些本文所述的式I化合物具有有效的抗病毒活性。 本发明还提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式I化合物。 本文所述的某些化合物抑制HCV复制复合物的组装。 本发明还提供含有一种或多种式I化合物或这些化合物的盐，溶剂化物或酰化前药以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。 本发明还包括通过向这些患者施用一定量的有效降低疾病体征或症状的式I化合物来治疗患有某些感染性疾病的患者的方法。 这些传染病包括病毒感染，特别是HCV感染。 本发明特别包括治疗患有感染性疾病的人类患者的方法，还包括治疗其它动物（包括患有传染病的家畜和驯养的伴侣动物）的方法。 治疗方法包括给予式I化合物作为单一活性剂或将一种式I化合物与一种或多种其它治疗剂组合施用。

    Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity
    6.
    发明申请
    Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity 失效
    具有抗HCV活性的化合物的取代的氨基噻唑前体药物

    公开(公告)号：US20090304605A1

    公开(公告)日：2009-12-10

    申请号：US12479213

    申请日：2009-06-05

    申请人： Cuixan Liu ,  Avinash Phadke ,  Xiangzhu Wang ,  Suoming Zhang

    发明人： Cuixan Liu ,  Avinash Phadke ,  Xiangzhu Wang ,  Suoming Zhang

    IPC分类号： A61K9/12 ,  C07D417/04 ,  A61K31/4439 ,  A61K31/675 ,  C07F9/58 ,  A61P31/12

    CPC分类号： C07D417/04 ,  C07D417/14

    摘要： The invention provides amino-substituted aminothiazole compounds of Formula I and Formula II where A is a group of the formula: and the variables X, Y, R, and R1 to R7 are described herein. These compounds are prodrugs of compounds useful as inhibitors of viral replication. Compositions containing such compounds, and methods of treating viral infections with these compounds, as well as to processes and intermediates useful for preparing such compounds are also provided by the invention.

    摘要翻译： 本发明提供式I和式II的氨基取代的氨基噻唑化合物，其中A是下式的基团：变量X，Y，R 1和R 1至R 7在本文中描述。 这些化合物是可用作病毒复制抑制剂的化合物的前药。 含有这些化合物的组合物，以及用这些化合物治疗病毒感染的方法，以及可用于制备这些化合物的方法和中间体也由本发明提供。

    Azabenzofuran substituted thioureas; inhibitors of viral replication
    9.
    发明申请
    Azabenzofuran substituted thioureas; inhibitors of viral replication 失效
    氮杂苯并呋喃取代的硫脲; 病毒复制抑制剂

    公开(公告)号：US20050228013A1

    公开(公告)日：2005-10-13

    申请号：US11029910

    申请日：2005-01-05

    申请人： Andrew Thurkauf ,  Dawei Chen ,  Avinash Phadke ,  Shouming Li ,  Milind Deshpande

    发明人： Andrew Thurkauf ,  Dawei Chen ,  Avinash Phadke ,  Shouming Li ,  Milind Deshpande

    IPC分类号： A61K31/00 ,  A61K31/4355 ,  A61K31/4741 ,  A61K38/21 ,  C07D471/04 ,  C07D491/02 ,  C07D491/04

    CPC分类号： A61K31/00 ,  A61K31/4355 ,  C07D491/04

    摘要： The present invention provides compounds of Formula 1, wherein the variables Ar, A1, A2, A3, A4, R5, R6, R7, V, W. X, and Y are defined herein. Certain compounds of Formula 1 described herein possess potent antiviral activity. The invention also provides compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.

    摘要翻译： 本发明提供式1的化合物，其中变量Ar，A 1，A 2，A 3，A 4， R 5，R 6，R 7，V，W，X和Y如本文所定义。 某些本文所述的式1的化合物具有有效的抗病毒活性。 本发明还提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式1化合物。 本发明还提供含有一种或多种式1化合物或这些化合物的盐，溶剂化物或酰化前药以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。 本发明还包括通过向这些患者施用一定量的有效减少疾病体征或症状的式1化合物来治疗患有某些感染性疾病的患者的方法。 这些传染病包括病毒感染，特别是HCV感染。 本发明特别包括治疗患有感染性疾病的人类患者的方法，还包括治疗其它动物（包括患有传染病的家畜和驯养的伴侣动物）的方法。 治疗方法包括施用作为单一活性剂的式1化合物或与一种或多种其它治疗剂组合施用式1的化合物。